Last reviewed · How we verify
IPTp-DP
IPTp-DP is a dihydroartemisinin-piperaquine combination that prevents malaria infection in pregnant women by killing malaria parasites in the blood.
IPTp-DP is a dihydroartemisinin-piperaquine combination that prevents malaria infection in pregnant women by killing malaria parasites in the blood. Used for Intermittent preventive therapy for malaria in pregnant women, Prevention of malaria in pregnancy in endemic areas.
At a glance
| Generic name | IPTp-DP |
|---|---|
| Also known as | Eurartesim, Duocotexin |
| Sponsor | Kenya Medical Research Institute |
| Drug class | Antimalarial combination therapy |
| Target | Plasmodium falciparum (malaria parasite) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | FDA-approved |
Mechanism of action
IPTp-DP (Intermittent Preventive Therapy in pregnancy using Dihydroartemisinin-Piperaquine) combines two antimalarial agents: dihydroartemisinin, a fast-acting artemisinin derivative that rapidly reduces parasite burden, and piperaquine, a longer-acting quinoline that provides sustained suppression. This combination is administered as seasonal or monthly doses during pregnancy to prevent malaria parasitemia and its adverse effects on maternal and fetal health.
Approved indications
- Intermittent preventive therapy for malaria in pregnant women
- Prevention of malaria in pregnancy in endemic areas
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Headache
Key clinical trials
- Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda (PHASE3)
- Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine in Papua, Indonesia (PHASE4)
- Improving PRegnancy Outcomes With PReVEntive Therapy in Africa-2 (IMPROVE-2) (PHASE3)
- The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract (PHASE3)
- Additional Screening With Sensitives RDTs and Malaria (PHASE3)
- Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa (PHASE3)
- Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination (PHASE3)
- Efficacy and Safety of IPTp-DP Versus IPTp-SP in Malawi (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPTp-DP CI brief — competitive landscape report
- IPTp-DP updates RSS · CI watch RSS
- Kenya Medical Research Institute portfolio CI